COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020

• Type of Material: Article
• Authors: Anna Acosta, Emory University; Adria L. Mathis, Centers for Disease Control and Prevention; Daniel Budnitz, Emory University; Andrew Geller, Emory University; Shua J. Chai, United States Public Health Service; Nisha B. Alden, Colorado Department of Public Health and Environment; James Meek, Yale School of Public Health; Evan Anderson, Emory University; Patricia Ryan, Michigan Department of Health and Human Services; Sue Kim, Michigan Department of Health and Human Services; Kathryn Como-Sabetti, Minnesota Department of Health; Salina Torres, New Mexico Department of Health; Elizabeth Dufort, New York State Department of Health; Nancy M. Bennett, University of Rochester; Laurie M. Billing, Ohio Department of Health; Melissa Sutton, Oregon Health Authority; H Keipp Talbot, Vanderbilt University; Andrea George, Salt Lake County Health Department; Huong Pham, Centers for Disease Control and Prevention; Aron J. Hall, Centers for Disease Control and Prevention; Alicia Fry, Centers for Disease Control and Prevention; Shikha Garg, Centers for Disease Control and Prevention; Lindsay Kim, Centers for Disease Control and Prevention
• Language: English
• Date: 2020-11-01
• Publisher: OXFORD UNIV PRESS INC
• Publication Version: Final Published Version
• Copyright Statement: 2020
• License: Creative Commons Universal : Public Domain Dedication
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofaa528
• Title of Journal or Parent Work: OPEN FORUM INFECTIOUS DISEASES
• Volume: 7
• Issue: 11
• Start Page: ofaa528
• End Page: ofaa528
• Grant/Funding Information: This work was supported by the Centers of Disease Control and Prevention through an Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00).
• Keywords: therapeutics; Life Sciences & Biomedicine; hospitalization; coronavirus; Immunology; Infectious Diseases; Microbiology; Science & Technology
• Research Categories: Health Sciences, Public Health; Biology, Microbiology; Health Sciences, Immunology

Abstract

Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.